NCT03690388 · OUTCOME

Objective Response Rate (ORR)

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy · Source last updated 2025-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 99% Confidence Interval
Time frame: Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.

What was measured

Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).

Analysis population: The first 100 subjects randomized.

Groups in this outcome

Cabozantinib

cabozantinib (60 mg) once daily orally (qd) Cabozantinib: Tablets containing 60-mg or 20-mg cabozantinib once daily orally.

Placebo

placebo once daily orally (qd) Placebo: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cabozantinib	67
Placebo	33

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 99% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Cabozantinib	15	Not reported	5.8	29.3	Not reported
Placebo	0	Not reported	0.0	14.8	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
5.8
upper Limit
29.3
value
15
group Id
OG001
lower Limit
0.0
upper Limit
14.8
value
0

denoms

counts
group Id
OG000
value
67
group Id
OG001
value
33
units
Participants

description

Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).

dispersion Type

99% Confidence Interval

groups

description
cabozantinib (60 mg) once daily orally (qd) Cabozantinib: Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
id
OG000
title
Cabozantinib
description
placebo once daily orally (qd) Placebo: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
id
OG001
title
Placebo

param Type

NUMBER

population Description

The first 100 subjects randomized.

reporting Status

POSTED

time Frame

Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.

title

Objective Response Rate (ORR)

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice